• Adult Malignant Glioma Therapeutics Market 2021, Focuses on Top Companies, Global Industry Analysis, Recent Trends and Regional Growth Forecast 2026For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/adult-malignant-glioma-therapeutics-market-100572
    Adult Malignant Glioma Therapeutics Market 2021, Focuses on Top Companies, Global Industry Analysis, Recent Trends and Regional Growth Forecast 2026For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/adult-malignant-glioma-therapeutics-market-100572
    WWW.FORTUNEBUSINESSINSIGHTS.COM
    Adult Malignant Glioma Therapeutics Market Report, 2026
    The global adult malignant glioma therapeutics market size stood at USD 1,459.1 million in 2018, is projected to reach USD 2,964.5 million by the end of 2026, exhibiting a CAGR of 9.3%
    0 Comments 0 Shares
  • The global respiratory syncytial virus (RSV) therapeutics market size is estimated to showcase potential growth owing to its increasing adoption against the prevention and treatment of the disease, observes Fortune Business Insights™ in an upcoming report, titled, “Respiratory Syncytial Virus (RSV) Therapeutics Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Prophylaxis and Treatment), By End-user (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) and Regional Forecast, 2020-2027.” The respiratory syncytial virus (RSV) therapeutics market stood at USD 1,111.3 million in 2019. It is projected to grow from USD 609.2 million in 2020 to USD 4,003.4 million in 2027 at a CAGR of 30.9% in the forecast period.

    For More Questions, Talk with Respiratory Syncytial Virus (RSV) Therapeutics Industry Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/respiratory-syncytial-virus-rsv-therapeutics-market-104668
    The global respiratory syncytial virus (RSV) therapeutics market size is estimated to showcase potential growth owing to its increasing adoption against the prevention and treatment of the disease, observes Fortune Business Insights™ in an upcoming report, titled, “Respiratory Syncytial Virus (RSV) Therapeutics Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Prophylaxis and Treatment), By End-user (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) and Regional Forecast, 2020-2027.” The respiratory syncytial virus (RSV) therapeutics market stood at USD 1,111.3 million in 2019. It is projected to grow from USD 609.2 million in 2020 to USD 4,003.4 million in 2027 at a CAGR of 30.9% in the forecast period. For More Questions, Talk with Respiratory Syncytial Virus (RSV) Therapeutics Industry Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/respiratory-syncytial-virus-rsv-therapeutics-market-104668
    WWW.FORTUNEBUSINESSINSIGHTS.COM
    Speak to Analyst - Respiratory Syncytial Virus (RSV) Therapeutics Market Size, Share and Global Industry Trend Forecast till 2025
    The global Respiratory Syncytial Virus (RSV) therapeutics market size stood at USD 1,111.3 million in 2019. The global impact of COVID-19 has been unprecedented and staggering, with RSV drugs experiencing a negative demand shock across all regio
    1
    0 Comments 0 Shares
  • The Navy announced Thursday it is getting ready to discharge those servicemen who refuse to receive experimental gene therapeutics, aka COVID vaccines, by a mandatory November 28 deadline. https://thenewamerican.com/navy-set-to-boot-servicemen-who-refuse-covid-jabs/
    The Navy announced Thursday it is getting ready to discharge those servicemen who refuse to receive experimental gene therapeutics, aka COVID vaccines, by a mandatory November 28 deadline. https://thenewamerican.com/navy-set-to-boot-servicemen-who-refuse-covid-jabs/
    THENEWAMERICAN.COM
    Navy Set to Boot Servicemen Who Refuse COVID Jabs - The New American
    The Navy announced Thursday it is getting ready to discharge those servicemen who refuse to receive experimental gene therapeutics, aka COVID vaccines, by a mandatory November 28 deadline. ...
    1 Comments 0 Shares
  • Hospitals Know They are Murdering People by Denying Effective #Therapeutics, Dr. Bryan Ardis Speaks

    https://freeworldnews.tv/watch?id=616a176ac903d74a70bc9650 #EarlyTreatmentWorks
    Hospitals Know They are Murdering People by Denying Effective #Therapeutics, Dr. Bryan Ardis Speaks https://freeworldnews.tv/watch?id=616a176ac903d74a70bc9650 #EarlyTreatmentWorks
    5
    2 Comments 0 Shares
  • First of all, it's not the 1st, it is an unkown, probably not the best or safest or certainly not the cheapest, and 2nd of all anything hyped and rushed through approval like this Molnupiravir by the Deep State 'Machine That IS', i'd say could be as bad as taking the vaccines. :

    --- from newsweek; Pharmaceutical company Merck and Florida-based Ridgeback Biotherapeutics announced Friday that they plan to seek emergency approval for an oral antiviral treatment for COVID-19.

    If authorized by the Food and Drug Administration (FDA), the drug, molnupiravir, (???)could be the first (??? WHAT ABOUT HCQ , Zinc Compounds and Ivermectin) oral antiviral treatment for patients with COVID-19. Merck said it planned to seek emergency use authorization in the U.S. as soon as possible and added that it will also be submitting applications for the drug to "regulatory agencies worldwide."

    The companies said that during a phase 3 trial, molnupiravir "significantly reduced the risk of hospitalization or death" in at-risk patients with mild or moderate cases of COVID-19. https://www.newsweek.com/what-molnupiravir-first-oral-covid-treatment-could-issued-years-end-1634656
    First of all, it's not the 1st, it is an unkown, probably not the best or safest or certainly not the cheapest, and 2nd of all anything hyped and rushed through approval like this Molnupiravir by the Deep State 'Machine That IS', i'd say could be as bad as taking the vaccines. : --- from newsweek; Pharmaceutical company Merck and Florida-based Ridgeback Biotherapeutics announced Friday that they plan to seek emergency approval for an oral antiviral treatment for COVID-19. If authorized by the Food and Drug Administration (FDA), the drug, molnupiravir, (???)could be the first (??? WHAT ABOUT HCQ , Zinc Compounds and Ivermectin) oral antiviral treatment for patients with COVID-19. Merck said it planned to seek emergency use authorization in the U.S. as soon as possible and added that it will also be submitting applications for the drug to "regulatory agencies worldwide." The companies said that during a phase 3 trial, molnupiravir "significantly reduced the risk of hospitalization or death" in at-risk patients with mild or moderate cases of COVID-19. https://www.newsweek.com/what-molnupiravir-first-oral-covid-treatment-could-issued-years-end-1634656
    WWW.NEWSWEEK.COM
    What is Molnupiravir? First oral COVID treatment could be issued by year's end
    The companies said that an interim analysis found molnupiravir reduced the risk of hospitalization or death by approximately 50 percent..
    0 Comments 2 Shares
  • The global respiratory syncytial virus (RSV) therapeutics market size is estimated to showcase potential growth owing to its increasing adoption against the prevention and treatment of the disease, observes Fortune Business Insights™ in an upcoming report, titled, “Respiratory Syncytial Virus (RSV) Therapeutics Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Prophylaxis and Treatment), By End-user (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) and Regional Forecast, 2020-2027.” The respiratory syncytial virus (RSV) therapeutics market stood at USD 1,111.3 million in 2019. It is projected to grow from USD 609.2 million in 2020 to USD 4,003.4 million in 2027 at a CAGR of 30.9% in the forecast period.

    Get Sample Report On Global Respiratory Syncytial Virus (RSV) Therapeutics Market: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/respiratory-syncytial-virus-rsv-therapeutics-market-104668
    The global respiratory syncytial virus (RSV) therapeutics market size is estimated to showcase potential growth owing to its increasing adoption against the prevention and treatment of the disease, observes Fortune Business Insights™ in an upcoming report, titled, “Respiratory Syncytial Virus (RSV) Therapeutics Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Prophylaxis and Treatment), By End-user (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) and Regional Forecast, 2020-2027.” The respiratory syncytial virus (RSV) therapeutics market stood at USD 1,111.3 million in 2019. It is projected to grow from USD 609.2 million in 2020 to USD 4,003.4 million in 2027 at a CAGR of 30.9% in the forecast period. Get Sample Report On Global Respiratory Syncytial Virus (RSV) Therapeutics Market: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/respiratory-syncytial-virus-rsv-therapeutics-market-104668
    WWW.FORTUNEBUSINESSINSIGHTS.COM
    Request Sample PDF - Respiratory Syncytial Virus (RSV) Therapeutics Market Size, Share and Global Industry Trend Forecast till 2025
    The global Respiratory Syncytial Virus (RSV) therapeutics market size stood at USD 1,111.3 million in 2019. The global impact of COVID-19 has been unprecedented and staggering, with RSV drugs experiencing a negative demand shock across all regio
    0 Comments 0 Shares
  • The global respiratory syncytial virus (RSV) therapeutics market size is estimated to showcase potential growth owing to its increasing adoption against the prevention and treatment of the disease, observes Fortune Business Insights™ in an upcoming report, titled, “Respiratory Syncytial Virus (RSV) Therapeutics Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Prophylaxis and Treatment), By End-user (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) and Regional Forecast, 2020-2027.” The respiratory syncytial virus (RSV) therapeutics market stood at USD 1,111.3 million in 2019. It is projected to grow from USD 609.2 million in 2020 to USD 4,003.4 million in 2027 at a CAGR of 30.9% in the forecast period.

    Browse More Information on This Report: https://www.fortunebusinessinsights.com/respiratory-syncytial-virus-rsv-therapeutics-market-104668
    The global respiratory syncytial virus (RSV) therapeutics market size is estimated to showcase potential growth owing to its increasing adoption against the prevention and treatment of the disease, observes Fortune Business Insights™ in an upcoming report, titled, “Respiratory Syncytial Virus (RSV) Therapeutics Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Prophylaxis and Treatment), By End-user (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) and Regional Forecast, 2020-2027.” The respiratory syncytial virus (RSV) therapeutics market stood at USD 1,111.3 million in 2019. It is projected to grow from USD 609.2 million in 2020 to USD 4,003.4 million in 2027 at a CAGR of 30.9% in the forecast period. Browse More Information on This Report: https://www.fortunebusinessinsights.com/respiratory-syncytial-virus-rsv-therapeutics-market-104668
    WWW.FORTUNEBUSINESSINSIGHTS.COM
    Respiratory Syncytial Virus (RSV) Therapeutics Market Report, 2027
    The global Respiratory Syncytial Virus (RSV) therapeutics market size stood at USD 1,111.3 million in 2019. The global impact of COVID-19 has been unprecedented and staggering, with RSV drugs experiencing a negative demand shock across all regio
    0 Comments 0 Shares
  • The global respiratory syncytial virus (RSV) therapeutics market size is estimated to showcase potential growth owing to its increasing adoption against the prevention and treatment of the disease, observes Fortune Business Insights™ in an upcoming report, titled, “Respiratory Syncytial Virus (RSV) Therapeutics Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Prophylaxis and Treatment), By End-user (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) and Regional Forecast, 2020-2027.” The respiratory syncytial virus (RSV) therapeutics market stood at USD 1,111.3 million in 2019. It is projected to grow from USD 609.2 million in 2020 to USD 4,003.4 million in 2027 at a CAGR of 30.9% in the forecast period.

    Browse More Information on This Report: https://www.fortunebusinessinsights.com/respiratory-syncytial-virus-rsv-therapeutics-market-104668
    The global respiratory syncytial virus (RSV) therapeutics market size is estimated to showcase potential growth owing to its increasing adoption against the prevention and treatment of the disease, observes Fortune Business Insights™ in an upcoming report, titled, “Respiratory Syncytial Virus (RSV) Therapeutics Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Prophylaxis and Treatment), By End-user (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) and Regional Forecast, 2020-2027.” The respiratory syncytial virus (RSV) therapeutics market stood at USD 1,111.3 million in 2019. It is projected to grow from USD 609.2 million in 2020 to USD 4,003.4 million in 2027 at a CAGR of 30.9% in the forecast period. Browse More Information on This Report: https://www.fortunebusinessinsights.com/respiratory-syncytial-virus-rsv-therapeutics-market-104668
    WWW.FORTUNEBUSINESSINSIGHTS.COM
    Respiratory Syncytial Virus (RSV) Therapeutics Market Report, 2027
    The global Respiratory Syncytial Virus (RSV) therapeutics market size stood at USD 1,111.3 million in 2019. The global impact of COVID-19 has been unprecedented and staggering, with RSV drugs experiencing a negative demand shock across all regio
    1
    0 Comments 0 Shares
  • Friend of mine just sent me this now:

    I've just rec'd this from a friend who's a nurse @ Sunnybrook Hospital, Toronto:

    DISTRIBUTE TO EVERYONE who does not want to be "vaccinated". All vaccines will no longer be justified from 20.10.2021: verified information. The European Union has approved (https://ec.europa.eu/commission/presscorner/detail/fr/ip_21_3299) 5 therapies that will be available in all hospitals in the Member States for the treatment of Covid. These therapies have been approved by a decree of the European Council (European Parliament) and will be in force from 1/10, so they will be distributed little by little around 20/10. Vaccines were approved on a “temporary experimental basis”. But since the decree will oblige to prescribe these 5 new drugs, the use of the vaccine will cease. So we understand why all the states said "between September it is necessary that ...". They already knew everything. You have to have patience. Do not accept any blackmail. Be patient. Now that ivermectin has been re-approved, there is no need for a vaccine. Great news. The Pasteur Institute recognizes the effectiveness of Ivermectin. One intake could eradicate all SARS covid-19 genetic material in some people. Read and share well.

    The good news: Ivermectin is now scientifically recognized as an effective drug, in the prophylaxis and treatment of Covid-19 by researchers at the Pasteur Institute in France. The results of their studies were published in the journal EMBO Molecular Medicine on July 12, 2021, so that’s recently. Analysis of the results of other research published in the American Journal of Therapeutics strongly calls, with supporting evidence, to bridge the guidelines of health agencies and include Ivermectin as a standard of care. Macron's government knew about it ...

    Be good and don’t hesitate to cheer up people who don’t want to get vaccinated
    https://www.lettre-docteur-rueff.fr/dr-rueff-biographie/
    https://www.lettre-docteur-rueff.fr/dr-rueff-biographie/
    Friend of mine just sent me this now: I've just rec'd this from a friend who's a nurse @ Sunnybrook Hospital, Toronto: DISTRIBUTE TO EVERYONE who does not want to be "vaccinated". All vaccines will no longer be justified from 20.10.2021: verified information. The European Union has approved (https://ec.europa.eu/commission/presscorner/detail/fr/ip_21_3299) 5 therapies that will be available in all hospitals in the Member States for the treatment of Covid. These therapies have been approved by a decree of the European Council (European Parliament) and will be in force from 1/10, so they will be distributed little by little around 20/10. Vaccines were approved on a “temporary experimental basis”. But since the decree will oblige to prescribe these 5 new drugs, the use of the vaccine will cease. So we understand why all the states said "between September it is necessary that ...". They already knew everything. You have to have patience. Do not accept any blackmail. Be patient. Now that ivermectin has been re-approved, there is no need for a vaccine. Great news. The Pasteur Institute recognizes the effectiveness of Ivermectin. One intake could eradicate all SARS covid-19 genetic material in some people. Read and share well. The good news: Ivermectin is now scientifically recognized as an effective drug, in the prophylaxis and treatment of Covid-19 by researchers at the Pasteur Institute in France. The results of their studies were published in the journal EMBO Molecular Medicine on July 12, 2021, so that’s recently. Analysis of the results of other research published in the American Journal of Therapeutics strongly calls, with supporting evidence, to bridge the guidelines of health agencies and include Ivermectin as a standard of care. Macron's government knew about it ... Be good and don’t hesitate to cheer up people who don’t want to get vaccinated https://www.lettre-docteur-rueff.fr/dr-rueff-biographie/ https://www.lettre-docteur-rueff.fr/dr-rueff-biographie/
    EC.EUROPA.EU
    Press corner
    Highlights, press releases and speeches
    0 Comments 1 Shares
  • https://www.twitch.tv/videos/1153872627 The Global Syndicate Takes a Hit: America Free Radio with Brooks Agnew Ivermectin Report Ivermectin Update American Journal of Therapeutics
    To date, very few treatments have been demonstrated to reduce the burden of morbidity and mortality from COVID-19. Although corticosteroids have been proven to reduce mortality in severe disease, there has been little convincing evidence on interventions that may prevent disease, reduce hospitalizations, and reduce the numbers of people progressing to critical disease and death.

    Ivermectin is a well-known medicine that is approved as an antiparasitic by the World Health Organization and the US Food and Drug Administration. It is widely used in low- and middle-income countries (LMICs) to treat worm infections. Also used for the treatment of scabies and lice, it is one of the World Health Organization’s Essential Medicines. With total doses of ivermectin distributed apparently equaling one-third of the present world population,5 ivermectin at the usual doses (0.2–0.4 mg/kg) is considered extremely safe for use in humans. In addition to its antiparasitic activity, it has been noted to have antiviral and anti-inflammatory properties, leading to an increasing list of therapeutic indications.

    Since the start of the SARS-CoV-2 pandemic, both observational and randomized studies have evaluated ivermectin as a treatment for, and as prophylaxis against, COVID-19 infection. A review by the Front Line COVID-19 Critical Care Alliance summarized findings from 27 studies on the effects of ivermectin for the prevention and treatment of COVID-19 infection, concluding that ivermectin “demonstrates a strong signal of therapeutic efficacy” against COVID-19. Another recent review found that ivermectin reduced deaths by 75%. Despite these findings, the National Institutes of Health in the United States recently stated that “there are insufficient data to recommend either for or against the use of ivermectin for the treatment of COVID-19," and the World Health Organization recommends against its use outside of clinical trials.

    Ivermectin has exhibited antiviral activity against a wide range of RNA and some DNA viruses, for example, Zika, dengue, yellow fever, and others demonstrated specific action against SARS-CoV-2 in vitro with a suggested host-directed mechanism of action being the blocking of the nuclear import of viral proteins that suppress normal immune responses. However, the necessary cell culture EC50 may not be achievable in vivo. Other conjectured mechanisms include inhibition of SARS-CoV-2 3CLPro activity (a protease essential for viral replication), a variety of anti-inflammatory effects, and competitive binding of ivermectin with the viral S protein as shown in multiple in silico studies.

    The latter would inhibit viral binding to ACE-2 receptors suppressing infection. Hemagglutination via viral binding to sialic acid receptors on erythrocytes is a recently proposed pathologic mechanism that would be similarly disrupted. Both host-directed and virus-directed mechanisms have thus been proposed, the clinical mechanism may be multimodal, possibly dependent on disease stage, and a comprehensive review of mechanisms of action is warranted.

    Developing new medications can take years; therefore, identifying existing drugs that can be repurposed against COVID-19 that already have an established safety profile through decades of use could play a critical role in suppressing or even ending the SARS-CoV-2 pandemic. Using repurposed medications may be especially important because it could take months, possibly years, for much of the world's population to get vaccinated, particularly among LMIC populations.

    Currently, ivermectin is commercially available and affordable in many countries globally. A 2018 application for ivermectin use for scabies gives a direct cost of $2.90 for 100 12-mg tablets. A recent estimate from Bangladesh reports a cost of US$0.60—US$1.80 for a 5-day course of ivermectin. For these reasons, the exploration of ivermectin's potential effectiveness against SARS-CoV-2 may be of particular importance for settings with limited resources. If demonstrated to be effective as a treatment for COVID-19, the cost-effectiveness of ivermectin should be considered against existing treatments and prophylaxes.

    The aim of this review was to assess the efficacy of ivermectin treatment among people with COVID-19 infection and as a prophylaxis among people at higher risk of COVID-19 infection. In addition, we aimed to prepare a brief economic commentary (BEC) of ivermectin as treatment and as prophylaxis for COVID-19.
    https://www.twitch.tv/videos/1153872627 The Global Syndicate Takes a Hit: America Free Radio with Brooks Agnew Ivermectin Report Ivermectin Update American Journal of Therapeutics To date, very few treatments have been demonstrated to reduce the burden of morbidity and mortality from COVID-19. Although corticosteroids have been proven to reduce mortality in severe disease, there has been little convincing evidence on interventions that may prevent disease, reduce hospitalizations, and reduce the numbers of people progressing to critical disease and death. Ivermectin is a well-known medicine that is approved as an antiparasitic by the World Health Organization and the US Food and Drug Administration. It is widely used in low- and middle-income countries (LMICs) to treat worm infections. Also used for the treatment of scabies and lice, it is one of the World Health Organization’s Essential Medicines. With total doses of ivermectin distributed apparently equaling one-third of the present world population,5 ivermectin at the usual doses (0.2–0.4 mg/kg) is considered extremely safe for use in humans. In addition to its antiparasitic activity, it has been noted to have antiviral and anti-inflammatory properties, leading to an increasing list of therapeutic indications. Since the start of the SARS-CoV-2 pandemic, both observational and randomized studies have evaluated ivermectin as a treatment for, and as prophylaxis against, COVID-19 infection. A review by the Front Line COVID-19 Critical Care Alliance summarized findings from 27 studies on the effects of ivermectin for the prevention and treatment of COVID-19 infection, concluding that ivermectin “demonstrates a strong signal of therapeutic efficacy” against COVID-19. Another recent review found that ivermectin reduced deaths by 75%. Despite these findings, the National Institutes of Health in the United States recently stated that “there are insufficient data to recommend either for or against the use of ivermectin for the treatment of COVID-19," and the World Health Organization recommends against its use outside of clinical trials. Ivermectin has exhibited antiviral activity against a wide range of RNA and some DNA viruses, for example, Zika, dengue, yellow fever, and others demonstrated specific action against SARS-CoV-2 in vitro with a suggested host-directed mechanism of action being the blocking of the nuclear import of viral proteins that suppress normal immune responses. However, the necessary cell culture EC50 may not be achievable in vivo. Other conjectured mechanisms include inhibition of SARS-CoV-2 3CLPro activity (a protease essential for viral replication), a variety of anti-inflammatory effects, and competitive binding of ivermectin with the viral S protein as shown in multiple in silico studies. The latter would inhibit viral binding to ACE-2 receptors suppressing infection. Hemagglutination via viral binding to sialic acid receptors on erythrocytes is a recently proposed pathologic mechanism that would be similarly disrupted. Both host-directed and virus-directed mechanisms have thus been proposed, the clinical mechanism may be multimodal, possibly dependent on disease stage, and a comprehensive review of mechanisms of action is warranted. Developing new medications can take years; therefore, identifying existing drugs that can be repurposed against COVID-19 that already have an established safety profile through decades of use could play a critical role in suppressing or even ending the SARS-CoV-2 pandemic. Using repurposed medications may be especially important because it could take months, possibly years, for much of the world's population to get vaccinated, particularly among LMIC populations. Currently, ivermectin is commercially available and affordable in many countries globally. A 2018 application for ivermectin use for scabies gives a direct cost of $2.90 for 100 12-mg tablets. A recent estimate from Bangladesh reports a cost of US$0.60—US$1.80 for a 5-day course of ivermectin. For these reasons, the exploration of ivermectin's potential effectiveness against SARS-CoV-2 may be of particular importance for settings with limited resources. If demonstrated to be effective as a treatment for COVID-19, the cost-effectiveness of ivermectin should be considered against existing treatments and prophylaxes. The aim of this review was to assess the efficacy of ivermectin treatment among people with COVID-19 infection and as a prophylaxis among people at higher risk of COVID-19 infection. In addition, we aimed to prepare a brief economic commentary (BEC) of ivermectin as treatment and as prophylaxis for COVID-19.
    0 Comments 0 Shares
No data to show
No data to show
No data to show
No data to show